Welcome to SYNTHIA Insight - a series of focused content pieces that bring the science behind SYNTHIA to life. Through interviews with our project partners, we explore views, visions and expertise in synthetic data. Each edition offers an accessible window into the objectives of SYNTHIA and the progress of our work - helping to engage the wider community, spark dialogue, and promote understanding of SYNTHIA’s mission and impact. We invite you to connect with the minds shaping the future of synthetic data.

In SYNTHIA Insight nr. 1 we introduce Saverio D’Amico, TRAIN CEO/ Co founder and AI Team Leader at Humanitas Research Hospital, Italy. D’Amico shares how his team is pushing boundaries with AI-generated multimodal synthetic data to accelerate personalised medicine in haematology. The interview is based on a study which is published in the journal of the American Society of Hematology ‘BLOOD’, titled: Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology. 

D’Amico offers an insightful overview of a pioneering study focused on generating multimodal longitudinal synthetic data—data that mirrors real patient conditions while ensuring privacy. The research, born from earlier collaborations (GenoMed4All and Synthema) is now extended within SYNTHIA, showcasing the strength of cross-project synergies under synthetic data projects funded by the European Union through Innovative Health Initiative and Horizon Europe. He explains how combining clinical, genomic, and imaging data helps build synthetic datasets that support better disease classification, risk assessment, and personalised treatments in haematology. D’Amico also addresses key challenges in creating synthetic data that is both realistic and representative, and how AI-powered generative models can overcome these hurdles. The interview underlines the role of SYNTHIA in furthering these techniques and ensuring their integration into clinical practice, with a strong emphasis on validation, fidelity, and privacy-by-design.

D’Amico states: 

“This new approach to develop multimodal synthetic data can significantly accelerate sustainable clinical trials.

We are very happy that TRAIN has the opportunity to develop this technology and validate it through a powerful initiative such as SYNTHIA”.

Highlights from the interview include: 

  • The development of SAFE, a validation framework ensuring accuracy, privacy, and clinical relevance 
  • The potential of synthetic data to support virtual clinical trials, and improve biomarker discovery 
  • A collaborative vision where SYNTHIA helps bridge AI research, clinical needs, and real-world implementation 

Watch the video interview: